Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Dose Frequency Reduction in sJIA
NCT01734382Phase 4Completed
- Sponsor
- Roche
- Start
- Jun 2013
- Primary completion
- Oct 2019
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 10
01
Overview
Phase 4, open-label trial of tocilizumab in systemic juvenile idiopathic arthritis (SJIA) (3 arms), sponsored by Roche. Primary endpoints: Juvenile Arthritis Disease Activity Score-71 up to 52 weeks, Number of Participants With JIA Disease Flare up to 52 weeks and 1 more. Started Jun 2013; status: completed.
02
Drugs
tocilizumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on NCT01734382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01734382.